Advertisement


Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the LUX-Lung 7 Trial (Spanish Language Version)

2016 ESMO Congress

Advertisement

Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses in Spanish overall survival data on afatinib vs gefitinib in patients with EGFR mutation–positive non–small cell lung cancer. (Abstract LBA43)



Related Videos

Skin Cancer

Christian U. Blank, MD, PhD, on Melanoma: Initial Data From the OpACIN Trial

Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses study findings on neoadjuvant ipilimumab plus nivolumab in patients with palpable stage III melanoma. (Abstract LBA39)

Gastrointestinal Cancer

Yung-Jue Bang, MD, PhD, on Gastric Cancer: Results From the GOLD Trial

Yung-Jue Bang, MD, PhD, of Seoul National University Hospital, discusses phase III study findings on olaparib and paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy. (Abstract LBA25)

Gynecologic Cancers

Mansoor Raza Mirza, MD, on Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial

Mansoor Raza Mirza, MD, of Rigshospitalet, Copenhagen University Hospital, discusses phase III study findings on maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer. (Abstract LBA3)

Lymphoma

Teresa Calimeri, MD, PhD, on DLBCL: Findings on High-Dose Methotrexate (Italian Language Version)

Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses in Italian high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk diffuse large B-cell lymphoma. (Abstract 908O)

Lung Cancer

Martin Reck, MD, PhD, on NSCLC: Results of KEYNOTE-024

Martin Reck, MD, PhD, of the LungenClinic, discusses study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung cancer with a PD-L1 tumor proportion score ≥50%. (Abstract LBA8)

Advertisement

Advertisement




Advertisement